1983
DOI: 10.1016/s0015-0282(16)47411-x
|View full text |Cite
|
Sign up to set email alerts
|

Ovulation induction with subcutaneous pulsatile gonadotropin-releasing hormone: singleton pregnancies in patients with previous multiple pregnancies after gonadotropin therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

1986
1986
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 36 publications
(5 citation statements)
references
References 17 publications
0
5
0
Order By: Relevance
“…Superficial phlebitis at IV sites and cellulitis at the site of SC catheters have been reported. 21 The largest prospective study to date Gonadotrophine Releasing Hormone Agonist As A Trigger of Ovulation in poly cystic ovary syndrome followed 230 catheters for 1958 catheter days. 22 Just 11% of all catheter tips cultured positive, and only 2% of 195 blood cultures were positive.…”
Section: Complicationsmentioning
confidence: 99%
“…Superficial phlebitis at IV sites and cellulitis at the site of SC catheters have been reported. 21 The largest prospective study to date Gonadotrophine Releasing Hormone Agonist As A Trigger of Ovulation in poly cystic ovary syndrome followed 230 catheters for 1958 catheter days. 22 Just 11% of all catheter tips cultured positive, and only 2% of 195 blood cultures were positive.…”
Section: Complicationsmentioning
confidence: 99%
“…60 Several studies also report ovulation and pregnancy after intermittent subcutaneous low-dose pulses of GnRH in women with presumed GnRH deficiency. 61 Although this treatment provides an effective and physiologic method of restoring reproductive function in FHA and minimizes the chance of multiple pregnancy, the GnRH pump is currently unavailable in the US and clinical trials are ongoing. 61 Kisspeptin, a principal regulatory protein important for initiating secretion of GnRH, has been studied in smaller pilot samples as an intravenous infusion however it is also not clinically available and more research is needed to demonstrate LH pulsatility.…”
Section: Treatment Optionsmentioning
confidence: 99%
“…61 Although this treatment provides an effective and physiologic method of restoring reproductive function in FHA and minimizes the chance of multiple pregnancy, the GnRH pump is currently unavailable in the US and clinical trials are ongoing. 61 Kisspeptin, a principal regulatory protein important for initiating secretion of GnRH, has been studied in smaller pilot samples as an intravenous infusion however it is also not clinically available and more research is needed to demonstrate LH pulsatility. 62 For these reasons, most physicians discuss in vitro fertilization as a safer and effective treatment option.…”
Section: Treatment Optionsmentioning
confidence: 99%
“…In these studies, LH-RH doses of 2.5 to 20 mcg per pulse were used with a pulse interval of 90 to 120 minutes. 39,[42][43][44][45][46][47][48] Based on these published studies, the overall pregnancy rate was 29.8% (Table 3), which 42 Reid,1981 32 Reid,1984 39 Seibel,1983 43 Skarin, 1983 44 Hurley, 1983 45 Hurley, 1984 40 Mason, 1984 46 Weinstein, 1984 47 Ross, 1985 48 No. of Patients is comparable to that found with intravenous administration of LH-RH.…”
Section: Therapeutic Use Of Lh-rh In Humansmentioning
confidence: 99%
“…Dosage schedules have been varied based on clinical response, and usually twice the dose of the intravenous LH-RH has been used for the subcutaneous infusions. The duration of LH-RH administration using the delivery time of the pump has varied from 10 to 240 seconds and does not appear to be critical according to published data 32,42,44,45 The resulting luteal phase could be maintained by continuing the LH-RH intermittently. However, most authors have used human chorionic gonadotropin, 2,500 IU per injection at 3 to 5 day intervals following ovulation.…”
Section: Therapeutic Use Of Lh-rh In Humansmentioning
confidence: 99%